B
Benny Sørensen
Researcher at Alnylam Pharmaceuticals
Publications - 93
Citations - 4909
Benny Sørensen is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Recombinant factor VIIa & Fibrinogen. The author has an hindex of 33, co-authored 93 publications receiving 4588 citations. Previous affiliations of Benny Sørensen include Aarhus University Hospital & King's College London.
Papers
More filters
Journal ArticleDOI
Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.
TL;DR: Data suggest that the whole blood coagulation TEG profile, following activation with minute amounts of TF, may reflect the hemostatic potential in patients suspected of impaired hemostasis.
Journal ArticleDOI
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
K. John Pasi,Savita Rangarajan,Pencho Georgiev,Tim Mant,Michael Desmond Creagh,Toshko Lissitchkov,David H. Bevan,Steve Austin,Charles R. M. Hay,Inga Hegemann,Rashid S. Kazmi,Pratima Chowdary,Liana Gercheva-Kyuchukova,Vasily Mamonov,Margarita Timofeeva,Chang-Heok Soh,Pushkal Garg,Akshay Vaishnaw,Akin Akinc,Benny Sørensen,Margaret V. Ragni +20 more
TL;DR: Once‐monthly subcutaneous administration of fitusiran resulted in dose‐dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.
Journal ArticleDOI
Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity
TL;DR: The aims of the present review are to examine thrombotic complications reported with P CCs, and to compare the safety of PCCs with human fresh frozen plasma, as reflected in the latest British and American guidelines.
Journal ArticleDOI
Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations
Christian Fenger-Eriksen,M. Lindberg-Larsen,A.Q. Christensen,Jørgen Ingerslev,Benny Sørensen,Benny Sørensen +5 more
TL;DR: Off-label substitution therapy with a fibrinogen concentrate generally improved global laboratory coagulation results and as supplementary intervention, appeared to diminish the requirements for RBC, FFP, and platelet substitution in this patient cohort.
Journal ArticleDOI
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Alfica Sehgal,Scott A Barros,Lacramioara Ivanciu,Brian C. Cooley,June Qin,Tim Racie,Julia Hettinger,Mary Carioto,Yongfeng Jiang,Josh Brodsky,Harsha K. Prabhala,Xuemei Zhang,Husain Attarwala,Renta Hutabarat,Don Foster,Stuart Milstein,Klaus Charisse,Satya Kuchimanchi,Martin Maier,Lubo Nechev,Pachamuthu Kandasamy,Alexander V Kel'in,Jayaprakash K. Nair,Kallanthottathil G. Rajeev,Muthiah Manoharan,Rachel Meyers,Benny Sørensen,Amy Simon,Yesim Dargaud,Claude Negrier,Rodney M. Camire,Akin Akinc +31 more
TL;DR: Treatment with ALN-AT3 promoted hemostasis in mouse models of hemophilia and led to improved thrombin generation in an NHP model of hemophile A with anti-factor VIII inhibitors.